Severe Intraocular Inflammation after Intravitreal Injection of Bevacizumab

Ophthalmology

Volumn 117, Issue 3, 2010, Pages

  Sato, Tatsuhiko ^a   Emi, Kazuyuki ^a   Ikeda, Toshihide ^a   Bando, Hajime ^a   Sato, Shigeru ^a   Morita, Shin ichi ^a   Oyagi, Tomohito ^a   Sawada, Kosaku ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEFTAZIDIME; VANCOMYCIN;

ADULT; AGED; ANTERIOR EYE CHAMBER; ANTERIOR EYE SEGMENT; ARTICLE; BACTERIUM CULTURE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CASE STUDY; CATARACT EXTRACTION; CELL DENSITY; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENDOPHTHALMITIS; ENDOTHELIUM CELL; EYE INFLAMMATION; FEMALE; HUMAN; HYPOPYON; INCIDENCE; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TOXIC ANTERIOR SEGMENT SYNDROME; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 77049116746     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.07.041     Document Type: Article

References (23)

1. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 22 (2004) 1198
2. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
3. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
4. Rabena M.D., Pieramici D.J., Castellarin A.A., et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27 (2007) 419-425
5. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
6. Kusaka S., Shima C., Wada K., et al. Efficacy of intravitreal injection of bevacizumab for sever retinopathy of prematurity: a pilot study. Br J Ophthalmol 92 (2008) 1450-1455
7. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
8. Shima C., Sakaguchi H., Gomi F., et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86 (2008) 372-376
9. Jonas J.B., Spandau U.H., Rensch F., et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 23 (2007) 240-242
10. Fintak D.R., Shah G.K., Blinder K.J., et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28 (2008) 1395-1399
11. Mamalis N., Edelhauser H.F., Dawson D.G., et al. Toxic anterior segment syndrome. J Cataract Refract Surg 32 (2006) 324-333
12. Bakri S.J., Snyder M.R., Pulido J.S., et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor alter withdrawal into a syringe and refrigeration of freezing. Retina 26 (2006) 519-522
13. Inoue Y., Usui M., Ohashi Y., et al., Preoperative Disinfection Study Group. Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: a prospective randomized multicenter study. Jpn J Ophthalmol 52 (2008) 151-161
14. Berkelman R.L., Holland B.W., and Anderson R.L. Increased bacterial activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 15 (1982) 635-639
15. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 140 (2005) 509-516
16. Nussenblatt R.B., Palestine A.G., Chan C.C., and Roberge F. Standardization of vitreous inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92 (1985) 467-471
17. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 113 (1995) 1479-1496
18. West E.S., Behrens A., McDonnell P.J., et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 112 (2005) 1388-1394
19. Wallin T., Parker J., Jin Y., et al. Cohort study of 27 cases of endophthalmitis at a single institution. J Cataract Refract Surg 31 (2005) 735-741
20. Bakri S.J., Snyder M.R., Reid J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
21. Roth D.B., Chieh J., Spirn M.J., et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121 (2003) 1279-1282
22. Wickremasinghe S.S., Michalova K., Gilhotra J., et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 115 (2008) 1911-1915
23. Bakri S.J., Larson T.A., and Edwards A.O. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 246 (2008) 779-781